Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints oncology development head

Dr Fouad Namouni promoted from head of medical

BMS Dr Fouad NamouniBristol-Myers Squibb has promoted Dr Fouad Namouni to oncology development head.

In his new role, Dr Namouni will oversee the development strategy for the pharmaceutical firm's oncology pipeline from early stage development through to commercialisation.

He will remain a member of the research and development leadership team, reporting to chief scientific officer and executive vice president Francis Cuss.

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions in research and development.

On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab). He most recently served as head of medical.

Cuss said: “Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb.

“As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients.

“I am confident that our oncology development programmes will continue to thrive under his leadership.”

27th July 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....